跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MVA-S
首页
药物
MVA-S
MVA-S
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
A RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) VACCINE AGAINST CORONAVIRUS DISEASE
EP 4164682 A1
申请人: BAVARIAN NORDIC AS
优先权: 2020
EP
US
WO
3 件公开
PR13.5 PROMOTER FOR ROBUST T-CELL AND ANTIBODY RESPONSES
EP 3778904 A1
申请人: BAVARIAN NORDIC AS
优先权: 2012
EP
US
3 件公开
Vaccinia virus vectors related to MVA with extensive genomic symmetries
US 11104884 B2
申请人: PROBIOGEN AG
优先权: 2017
CN
US
2 件公开
POXVIRUS-PLASMODIUM RECOMBINANTS, COMPOSITIONS CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND METHODS OF MAKING AND USING SAME
US 2015191704 A1
申请人: PAOLETTI ENZO
优先权: 2014
US
2 件公开
Recombinant vectors based on the modified vaccinia ankara (mva) virus as vaccines against lieshmaniasis
US 2010172933 A1
申请人: PEREZ JIMENEZ EVA
优先权: 2005
US
MVA virus and uses thereof
US 9732325 B2
申请人: PROBIOGEN AG
优先权: 2012
US
MVA-BASED VACCINE AGAINST COVID-19 EXPRESSING A PREFUSION-STABILIZED SARS-COV-2 S PROTEIN
EP 4108257 A1
申请人: CONSEJO SUPERIOR INVESTIGACION
优先权: 2021
EP
MULTIGENIC MVA-SARS-COV-2 VACCINE
US 2022370600 A1
申请人: UNIV TEXAS
优先权: 2022
US
Recombinant vector vaccine for expressing novel coronavirus S protein, recombinant virus vaccine and application
CN 117327736 A
申请人: UNIV CHINA AGRICULTURAL
优先权: 2023
CN
药物
反馈